Research Analysis · Aspirin & healthy aging
ASPREE found no gain in disability-free survival—and more major bleeding
In 19,114 selected older adults, daily low-dose aspirin did not improve the trial’s composite of death, dementia or persistent physical disability over a median 4.7 years. Major hemorrhage was higher.
Discovery, counterevidence, claim mapping, identifiers, funding, correction state and prose were reviewed before release.
Evidence at a glance
One large randomized primary-prevention trial
- Study type
- Randomized, double-blind, placebo-controlled trial
- Studied in
- Humans
- Participants / sample
- 19,114 community-dwelling older adults without cardiovascular disease, dementia or independence-limiting physical disability at enrollment
- Publication status
- Peer reviewed; no linked correction, retraction or expression of concern identified as of verification
- Outcome type
- Composite of death, dementia or persistent physical disability; major hemorrhage reported separately
- Evidence maturity
- Large human randomized evidence over median 4.7 years, with lower adherence late in follow-up
- Conflicts / funding
- Public and institutional funding; Bayer supplied aspirin and matching placebo in kind and was reported to have no other trial role
- Our assessment
- No demonstrated gain in disability-free survival; major hemorrhage was higher with aspirin
Read this first
Three takeaways
- The composite occurred at 21.5 events per 1,000 person-years with aspirin and 21.2 with placebo; hazard ratio 1.01, 95% CI 0.92–1.11.
- “Disability-free survival” combined death, dementia and persistent physical disability. It is not the same as lifespan, and its components must be interpreted separately.
- Major hemorrhage occurred in 3.8% with aspirin and 2.8% with placebo; hazard ratio 1.38, 95% CI 1.18–1.62.
Keep outcomes separate
A composite is not every outcome at once
Death
All-cause mortality was a separate secondary outcome with an unexpected imbalance.
Dementia
The component did not show a substantial between-group difference in this analysis.
Disability
Persistent physical disability was defined separately from short-lived functional change.
Bleeding
Major hemorrhage was a measured harm, not part of a personalized benefit–risk score.
The bottom line
Starting 100 mg daily enteric-coated aspirin did not extend ASPREE’s disability-free-survival composite in selected older adults over a median 4.7 years. Major hemorrhage was more common with aspirin.
What researchers did
Investigators randomly assigned 9,525 participants to aspirin and 9,589 to placebo. Most entered at age 70 or older; Black and Hispanic US participants could enter at 65 or older. People with cardiovascular disease, dementia, significant disability, a clinical aspirin indication or increased bleeding risk were excluded.
What they found
The composite rate was 21.5 versus 21.2 events per 1,000 person-years; HR 1.01, 95% CI 0.92–1.11, P=.79. Assigned-treatment adherence in the final year was 62.1% with aspirin and 64.1% with placebo.
How strong is the evidence?
This was a large, blinded randomized trial with a published protocol, a prespecified statistical plan and adjudicated outcomes. Its strongest inference is about assignment to this dose in this primary-prevention population over the observed period.
What this does not show
The result does not prove aspirin has zero effect in every group, erase individual components, or apply to people with established cardiovascular disease. Disability-free survival is not a direct lifespan measure.
Safety, guidance and conflicts
Major hemorrhage was higher with aspirin. The April 26, 2022 USPSTF recommendation advises against initiating low-dose aspirin for primary prevention in adults 60 or older. FDA says preventive aspirin is not right for everyone and can cause serious bleeding. Bayer supplied study product but was reported to have no other trial role.
What happens next
Longer follow-up can clarify later outcomes, but years after assigned treatment stops require a different inference. Future evidence would need to preserve prevention setting, adherence, absolute harms and the composite’s component outcomes.
Educational boundary
This article explains a population trial and dated guidance. It does not tell anyone to start, continue, stop or change aspirin. Those decisions depend on indication, bleeding risk, other medicines and clinical history.
Primary sources
Sources, roles and limits
- ASPREE disability-free-survival analysis
- Identifier
- PMID:30221596 · PMCID:PMC6426126 · DOI:10.1056/NEJMoa1800722 · NCT01038583
- Role
- Primary randomized support
- Limitation
- Selected primary-prevention population; median 4.7 years and declining adherence.
- ASPREE registry
- Identifier
- NCT01038583
- Role
- Trial identity, eligibility, sponsor and results context
- Limitation
- Registration is not a recommendation or government endorsement.
- ASPREE trial design
- Identifier
- PMID:24113028 · DOI:10.1016/j.cct.2013.09.014
- Role
- Protocol and outcome definitions
- Limitation
- Published before final results.
- ASPREE statistical analysis plan
- Identifier
- PMID:29111960 · DOI:10.1177/1747493017741383
- Role
- Prespecified analysis context
- Limitation
- Does not replace the results publication.
- USPSTF aspirin recommendation
- Identifier
- April 26, 2022
- Role
- Dated US primary-prevention context
- Limitation
- Initiation guidance is not an individual medication decision or secondary-prevention rule.
- FDA aspirin facts
- Identifier
- FDA page checked August 3, 2026
- Role
- Current bleeding and clinician-guidance context
- Limitation
- General safety information does not determine one person’s treatment.
Connected topics
Continue through the knowledge system
Continue with real coverage
Keep reading
These are learning paths, not rankings or recommendations.
Another large primary-prevention trial with benefits and harms kept separate
SPRINT reduced cardiovascular events—not aging itself
Intensive treatment lowered cardiovascular events and mortality in eligible high-risk adults, with more hypotension, electrolyte problems and kidney injury.
Evidence scopeHuman clinical outcomes · large randomized trial
A trial that measured a concrete disability outcome rather than a broad aging claim
Structured physical activity reduced late-life mobility disability—not aging itself
LIFE supports a meaningful mobility outcome in vulnerable older adults, while lifespan and universal-program claims remain untested.
Evidence scopeHuman function · randomized trials
Another long follow-up where practiced outcomes and broader healthy-aging claims differ
Cognitive training improved practiced skills—not survival or proven dementia prevention
ACTIVE supports trained-ability gains and some function signals, found no mortality benefit, and leaves a claims-based dementia subgroup methodologically disputed.
Evidence scopeHuman trained abilities and long-term outcomes · randomized trial plus disputed secondary analysis
Disclosures and history
- August 3, 2026 — source discovery and independent verification completed before prose drafting.
- August 3, 2026 — population, composite, adherence, safety, funding and prevention-setting boundaries reviewed.
- Corrections: no linked correction, retraction or expression of concern identified for the featured records as of verification; guidance and registry records must be rechecked when this story is updated.